#antiviral

Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.

Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.

Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.

The new drugs must be used within a narrow window of time after developing symptoms.

Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.

Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.

People under 50 who were cured of hepatitis C were at comparable risk to the general population.

The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats

Positive diagnostic tests and drug prescriptions dropped 40% in July 2020 compared with earlier years.

Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.

Assessing patient-reported outcomes can support treatment for hard-to-reach populations.

People who received treatment had a lower composite risk of cirrhosis, liver cancer and death.

The risk was lower in people who had achieved a sustained virological response compared with those who had not.

No significant links were found between liver stiffness prior to antiviral treatment and cirrhosis, liver cancer or transplants or death.

Mental health professionals should take a more active role in the HCV treatment arena.

New app allows people living with HCV to take part in a research study aimed at tracking antiviral medication effects.